Interleukin-10/NN
Polymorphisms/NNS
in/IN
Association/NN
with/IN
Prognosis/NN
in/IN
Patients/NNS
with/IN
B-Cell/JJ
Lymphoma/NN
Treated/JJ
by/IN
R-CHOP/NN
./.
====================
Interleukin-10/NN
(/(
IL10/NN
)/)
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
initiating/VBG
and/CC
maintaining/VBG
an/DT
appropriate/JJ
immune/JJ
response/NN
to/TO
non-Hodgkin/JJ
lymphoma/NN
(/(
NHL/NN
)/)
./.
====================
Previous/JJ
studies/NNS
have/VBP
revealed/VBN
that/IN
the/DT
transcription/NN
of/IN
IL10/NN
mRNA/NN
and/CC
its/PRP$
protein/NN
expression/NN
may/MD
be/VB
infl/JJ
uenced/JJ
by/IN
several/JJ
single-nucleotide/JJ
polymorphisms/NNS
in/IN
the/DT
promoter/NN
and/CC
intron/NN
regions/NNS
,/,
including/VBG
rs1800896/NN
,/,
rs1800871/NN
,/,
and/CC
rs1800872/NN
./.
====================
However/RB
,/,
the/DT
impact/NN
of/IN
polymorphisms/NNS
of/IN
the/DT
IL10/NN
gene/NN
on/IN
NHL/NN
prognosis/NN
has/VBZ
not/RB
been/VBN
fully/RB
elucidated/VBN
./.
====================
Here/RB
,/,
we/PRP
investigated/VBD
the/DT
association/NN
between/IN
IL10/NN
polymorphisms/NNS
and/CC
NHL/NN
prognosis/NN
./.
====================
This/DT
study/NN
involved/VBD
112/CD
NHL/NN
patients/NNS
treated/VBN
at/IN
the/DT
National/JJ
Cancer/NN
Center/NN
,/,
Korea/NN
./.
====================
The/DT
median/JJ
age/NN
was/VBD
57/CD
years/NNS
,/,
and/CC
70/CD
patients/NNS
(/(
62.5/CD
%/NN
)/)
were/VBD
men/NNS
./.
====================
Clinical/JJ
characteristics/NNS
,/,
including/VBG
age/NN
,/,
performance/RB
status/NN
,/,
stage/NN
,/,
and/CC
extra-nodal/JJ
involvement/NN
,/,
as/IN
well/RB
as/IN
cell/NN
lineage/NN
and/CC
International/JJ
Prognostic/JJ
Index/NN
(/(
IPI/NN
)/)
,/,
were/VBD
evaluated/VBN
./.
====================
A/DT
total/JJ
of/IN
four/CD
polymorphisms/NNS
in/IN
IL10/NN
with/IN
heterozygous/JJ
alleles/NNS
were/VBD
analyzed/VBN
for/IN
hazard/JJ
ratios/NNS
of/IN
overall/JJ
survival/NN
(/(
OS/NNS
)/)
and/CC
progression-free/JJ
survival/NN
(/(
PFS/NN
)/)
using/VBG
Cox/NN
proportional/JJ
hazards/VBZ
regression/NN
analysis/NN
./.
====================
Diffuse/IN
large/JJ
B-cell/NN
lymphoma/NN
was/VBD
the/DT
most/JJS
common/JJ
histologic/JJ
type/NN
(/(
n/NN
=/JJ
83/CD
)/)
,/,
followed/VBN
by/IN
T-cell/NN
lymphoma/NN
(/(
n/NN
=/JJ
18/CD
)/)
,/,
mantle/NN
cell/NN
lymphoma/NN
(/(
n/NN
=/JJ
6/CD
)/)
,/,
and/CC
others/NNS
(/(
n/NN
=/JJ
5/CD
)/)
./.
====================
Cell/NN
lineage/NN
,/,
IPI/NN
,/,
and/CC
extra-nodal/JJ
involvement/NN
were/VBD
predictors/NNS
of/IN
prognosis/NN
./.
====================
In/IN
the/DT
additive/JJ
genetic/JJ
model/NN
results/VBZ
for/IN
each/DT
IL10/NN
polymorphism/NN
,/,
the/DT
rs1800871/NN
and/CC
rs1800872/NN
polymorphisms/NNS
represented/VBN
a/DT
marginal/JJ
association/NN
with/IN
OS/NN
(/(
p/NN
=/JJ
0.09/CD
and/CC
p/NN
=/JJ
0.06/CD
)/)
and/CC
PFS/NN
(/(
p/NN
=/JJ
0.05/CD
and/CC
p/NN
=/JJ
0.08/CD
)/)
in/IN
B-cell/NN
lymphoma/NN
patients/NNS
treated/VBN
with/IN
rituximab/NN
plus/CC
cyclophosphamide/NN
,/,
doxorubicin/NN
,/,
vincristine/RB
,/,
and/CC
prednisone/NN
(/(
R-CHOP/NN
)/)
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
IL10/NN
polymorphisms/NNS
might/MD
be/VB
prognostic/JJ
indicators/NNS
for/IN
patients/NNS
with/IN
B-cell/NN
NHL/NN
treated/JJ
with/IN
R-CHOP/NN
./.
====================
The/DT
incidence/NN
rate/NN
of/IN
hematologic/JJ
malignancies/NNS
has/VBZ
steadily/RB
increased/VBD
during/IN
recent/JJ
decades/NNS
in/IN
many/JJ
regions/NNS
./.
====================
Non-Hodgkin/NN
lymphoma/NN
(/(
NHL/NN
)/)
is/VBZ
the/DT
most/JJS
frequent/JJ
hematologic/JJ
cancer/NN
type/NN
,/,
accounting/VBG
for/IN
43/CD
%/NN
of/IN
all/DT
hematologic/JJ
malignancies/NNS
and/CC
90/CD
%/NN
of/IN
lymphomas/NNS
[/(
1/CD
]/)
./.
====================
In/IN
Korea/NN
,/,
the/DT
incidence/NN
of/IN
NHL/NN
is/VBZ
approximately/RB
10.8/CD
per/FW
100,000/CD
persons/NNS
per/FW
year/NN
[/(
2/CD
]/)
./.
====================
The/DT
risk/NN
of/IN
NHL/NN
is/VBZ
increased/VBN
by/IN
age/NN
,/,
chronic/JJ
infection/NN
,/,
and/CC
genetic/JJ
and/CC
environmental/JJ
factors/NNS
[/(
3/CD
]/)
./.
====================
The/DT
frequency/NN
of/IN
B-cell/NN
lymphoma/NN
is/VBZ
higher/JJR
than/IN
that/DT
of/IN
T-cell/NN
lymphoma/NN
in/IN
NHL/NN
,/,
and/CC
the/DT
survival/NN
rate/NN
of/IN
B-cell/NN
lymphoma/NN
has/VBZ
continuously/RB
improved/VBD
./.
====================
The/DT
prognosis/NN
varies/VBZ
,/,
depending/VBG
on/IN
patient/NN
age/NN
,/,
clinicopathological/JJ
features/NNS
,/,
and/CC
genetic/JJ
factors/NNS
./.
====================
The/DT
International/JJ
Prognostic/JJ
Index/NN
(/(
IPI/NN
)/)
is/VBZ
the/DT
most/JJS
commonly/RB
used/VBN
tool/NN
to/TO
predict/VB
the/DT
prognosis/NN
of/IN
NHL/NN
[/(
45/CD
]/)
./.
====================
However/RB
,/,
its/PRP$
efficiency/NN
could/MD
be/VB
enhanced/VBN
by/IN
the/DT
inclusion/NN
of/IN
additional/JJ
prognostic/JJ
markers/NNS
./.
====================
Interleukin-10/NN
(/(
IL-10/NN
)/)
,/,
one/CD
of/IN
the/DT
Th2/NN
anti-inflammatory/JJ
cytokines/NNS
,/,
is/VBZ
mainly/RB
secreted/VBN
by/IN
type/NN
2/CD
helper/NN
T-cells/NNS
(/(
Th2/NN
)/)
and/CC
activates/VBZ
T-cells/NNS
and/CC
monocytes/NNS
,/,
as/IN
well/RB
as/IN
B/NN
lymphocytes/NNS
./.
====================
IL-10/NN
can/MD
promote/VB
cancer/NN
by/IN
immunosuppression/NN
or/CC
stimulation/NN
of/IN
cell/NN
proliferation/NN
(/(
B-cells/NNS
and/CC
Th2-cells/NNS
)/)
and/CC
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
the/DT
regulation/NN
of/IN
inflammation/NN
by/IN
suppressing/VBG
the/DT
release/NN
and/CC
function/NN
of/IN
Th1/NN
pro-inflammatory/JJ
cytokines/NNS
[/(
6/CD
]/)
./.
====================
Recent/JJ
evidence/NN
suggests/VBZ
that/IN
the/DT
imbalance/NN
of/IN
the/DT
Th1/Th2/NN
response/NN
induced/VBN
by/IN
genetic/JJ
variants/NNS
affects/VBZ
the/DT
pathogenesis/NN
of/IN
NHL/NN
[/(
7/CD
]/)
./.
====================
These/DT
findings/NNS
indicate/VBP
that/IN
IL10/NN
polymorphism/NN
may/MD
be/VB
a/DT
principal/JJ
mediator/NN
cytokine/NN
in/IN
the/DT
pathogenesis/NN
of/IN
NHL/NN
./.
====================
The/DT
IL10/NN
gene/NN
is/VBZ
positioned/VBN
on/IN
chromosome/NN
1/CD
(/(
1q31–1q32/NN
)/)
./.
====================
Previous/JJ
studies/NNS
have/VBP
revealed/VBN
that/IN
the/DT
transcription/NN
of/IN
IL10/NN
mRNA/NN
and/CC
its/PRP$
protein/NN
expression/NN
may/MD
be/VB
influenced/VBN
by/IN
some/DT
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
in/IN
the/DT
promoter/NN
region/NN
,/,
including/VBG
rs1800896/NN
,/,
rs1800871/NN
,/,
and/CC
rs1800872/NN
[/(
78/CD
]/)
./.
====================
However/RB
,/,
the/DT
impact/NN
of/IN
polymorphisms/NNS
of/IN
the/DT
IL10/NN
gene/NN
on/IN
NHL/NN
prognosis/NN
has/VBZ
not/RB
been/VBN
fully/RB
elucidated/VBN
./.
====================
Here/RB
,/,
we/PRP
investigated/VBD
the/DT
association/NN
between/IN
IL10/NN
polymorphisms/NNS
and/CC
NHL/NN
prognosis/NN
./.
====================
Patients/NNS
and/CC
collection/NN
of/IN
clinical/JJ
data/NNS
====================
This/DT
study/NN
recruited/VBD
112/CD
patients/NNS
diagnosed/VBD
with/IN
NHL/NN
at/IN
the/DT
National/JJ
Cancer/NN
Center/NN
in/IN
Korea/NN
from/IN
2005/CD
to/TO
2012/CD
./.
====================
Patients/NNS
gave/VBD
informed/VBN
consent/NN
,/,
which/WDT
was/VBD
approved/VBN
by/IN
the/DT
institutional/JJ
review/NN
board/JJ
./.
====================
Inclusion/NN
criteria/NNS
were/VBD
as/IN
follows/VBZ
:/:
(/(
1/LS
)/)
ethnically/RB
Korean/JJ
;/:
(/(
2/CD
)/)
available/JJ
samples/NNS
at/IN
diagnosis/NN
;/:
and/CC
(/(
3/LS
)/)
diagnosed/VBD
with/IN
non-Hodgkin/JJ
lymphoma/NN
on/IN
the/DT
basis/NN
of/IN
World/NN
Health/NN
Organization/NN
(/(
WHO/NN
)/)
guidelines/NNS
[/(
9/CD
]/)
,/,
with/IN
or/CC
without/IN
treatment/NN
with/IN
an/DT
rituximab/NN
plus/CC
cyclophosphamide/NN
,/,
doxorubicin/NN
,/,
vincristine/RB
,/,
and/CC
prednisolone/NN
(/(
R-CHOP/NN
)/)
regimen/RB
./.
====================
There/EX
were/VBD
no/DT
recruitment/NN
restrictions/NNS
with/IN
regard/NN
to/TO
gender/VB
or/CC
cancer/NN
stage/NN
./.
====================
The/DT
mean/JJ
age/NN
of/IN
patients/NNS
was/VBD
56/CD
years/NNS
,/,
and/CC
62.5/CD
%/NN
of/IN
cases/NNS
were/VBD
male/JJ
./.
====================
Chemotherapy/NN
was/VBD
repeated/VBN
every/RB
3/CD
weeks/NNS
for/IN
a/DT
total/JJ
of/IN
six/CD
to/TO
eight/CD
cycles/NNS
,/,
as/IN
decided/VBN
by/IN
the/DT
clinician/JJ
./.
====================
After/IN
every/RB
three/CD
cycles/NNS
,/,
the/DT
therapeutic/JJ
response/NN
was/VBD
evaluated/VBN
./.
====================
Follow-up/NN
was/VBD
performed/VBN
every/RB
3/CD
months/NNS
for/IN
the/DT
first/JJ
2/CD
years/NNS
;/:
thereafter/RB
,/,
the/DT
interval/JJ
was/VBD
extended/VBN
to/TO
every/DT
6/CD
months/NNS
./.
====================
Information/NN
on/IN
demographic/JJ
characteristics/NNS
,/,
including/VBG
age/NN
,/,
IPI/NN
,/,
performance/RB
status/NN
by/IN
WHO/NN
,/,
cancer/NN
stage/NN
,/,
and/CC
extra-nodal/JJ
involvement/NN
,/,
were/VBD
evaluated/VBN
and/CC
analyzed/VBD
./.
====================
Candidate/NN
polymorphisms/NNS
and/CC
genotyping/VBG
====================
Five/CD
polymorphism/NN
sites/NNS
were/VBD
selected/VBN
,/,
based/VBN
on/IN
a/DT
review/NN
of/IN
the/DT
literature/NN
and/CC
a/DT
genetic/JJ
database/NN
./.
====================
We/PRP
searched/VBD
the/DT
literature/NN
using/VBG
the/DT
keywords/JJ
‘/CD
IL-10/NN
,/,
polymorphism/NN
,/,
and/CC
cancer/NN
’/RB
in/IN
3/CD
years/NNS
and/CC
decided/VBD
to/TO
include/VB
five/CD
SNPs/NNS
(/(
rs1800896/CD
,/,
rs1800871/NN
,/,
rs1800872/NN
,/,
rs3021094/NN
,/,
and/CC
rs1554286/NN
)/)
,/,
which/WDT
are/VBP
located/JJ
in/IN
the/DT
promotor/NN
and/CC
intron/NN
regions/NNS
of/IN
the/DT
IL-10/NN
gene/NN
./.
====================
These/DT
SNPs/NNS
have/VBP
been/VBN
reported/VBN
as/IN
having/VBG
a/DT
significant/JJ
association/NN
with/IN
cancer/NN
more/RBR
than/IN
once/RB
out/IN
of/IN
45/CD
publications/NNS
./.
====================
Among/IN
them/PRP
,/,
rs1800896/NN
was/VBD
excluded/VBN
from/IN
the/DT
analysis/NN
,/,
because/IN
its/PRP$
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
was/VBD
0.027/CD
./.
====================
Genomic/JJ
DNA/NN
was/VBD
extracted/VBN
from/IN
patients/NNS
'/``
peripheral/JJ
blood/NN
using/VBG
a/DT
QIAamp/NN
DNA/NN
Blood/NN
Mini/NNS
Kit/NN
(/(
Qiagen/NN
,/,
Valencia/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
and/CC
SNPs/NNS
were/VBD
genotyped/VBN
using/VBG
a/DT
Taqman/JJ
5/CD
'/``
nuclease/NN
assay/NN
for/IN
allelic/JJ
discrimination/NN
with/IN
commercially/RB
available/JJ
Taqman/JJ
probes/NNS
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
Briefly/RB
,/,
genotyping/VBG
reactions/NNS
were/VBD
carried/VBN
out/RP
in/IN
a/DT
volume/NN
of/IN
5/CD
µL/NN
,/,
containing/VBG
10/CD
ng/NN
of/IN
genomic/JJ
DNA/NN
,/,
2.5/CD
µL/NN
of/IN
TaqMan/JJ
Genotyping/JJ
Master/NN
Mix/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
,/,
and/CC
genotyping/VBG
probe/NN
,/,
in/IN
a/DT
384-well/JJ
plate/VBP
./.
====================
Genotyping/VBG
results/NNS
were/VBD
analyzed/VBN
with/IN
an/DT
ABI/NN
7900HT/CD
Sequence/NN
Detection/NN
System/NN
(/(
Applied/VBN
Biosystems/NNS
)/)
by/IN
applying/VBG
allelic/JJ
discrimination/NN
plots/NNS
using/VBG
SDS/NN
2.1/CD
software/RB
(/(
version/NN
5.0/CD
;/:
Applied/VBN
Biosystems/NNS
)/)
./.
====================
Genotyping/VBG
results/NNS
were/VBD
confirmed/VBN
by/IN
independently/RB
replicating/VBG
genotyping/VBG
reactions/NNS
for/IN
10/CD
%/NN
of/IN
the/DT
samples/NNS
,/,
and/CC
all/DT
genotypes/NNS
were/VBD
the/DT
same/JJ
./.
====================
Statistical/JJ
analyses/NNS
====================
Associations/NNS
between/IN
clinicopathological/JJ
factors/NNS
,/,
including/VBG
age/NN
,/,
IPI/NN
,/,
performance/RB
status/NN
by/IN
WHO/NN
,/,
cancer/NN
stage/NN
,/,
and/CC
extra-nodal/JJ
involvement/NN
,/,
and/CC
patients/NNS
'/``
survival/NN
were/VBD
analyzed/VBN
using/VBG
univariable/JJ
or/CC
multivariable/JJ
Cox/NN
proportional/JJ
hazards/VBZ
regression/NN
models/NNS
./.
====================
All/DT
polymorphisms/NNS
were/VBD
in/IN
Hardy-Weinberg/JJ
equilibrium/NN
,/,
with/IN
p-values/NNS
greater/JJR
than/IN
0.05/CD
using/VBG
HWE.test/JJ
in/IN
R/NN
package/NN
{/CD
genetics/NNS
}/CD
[/(
10/CD
]/)
./.
====================
Three/CD
different/JJ
genetic/JJ
models—additive/JJ
,/,
dominant/JJ
,/,
and/CC
recessive—were/VBP
used/VBN
to/TO
assess/VB
each/DT
SNP/NN
's/POS
effect/NN
on/IN
the/DT
hazard/JJ
ratios/NNS
(/(
HRs/NNS
)/)
for/IN
survival/NN
./.
====================
Overall/RB
survival/NN
(/(
OS/NNS
)/)
was/VBD
calculated/VBN
from/IN
the/DT
day/NN
of/IN
diagnosis/NN
to/TO
the/DT
day/NN
of/IN
last/JJ
follow-up/JJ
or/CC
death/NN
./.
====================
Progression-free/JJ
survival/NN
(/(
PFS/NN
)/)
was/VBD
measured/VBN
from/IN
the/DT
day/NN
of/IN
diagnosis/NN
to/TO
the/DT
day/NN
of/IN
progression/NN
or/CC
death/NN
./.
====================
Patients/NNS
who/WP
were/VBD
alive/JJ
at/IN
the/DT
time/NN
of/IN
follow-up/JJ
were/VBD
censored/VBN
./.
====================
The/DT
effects/NNS
of/IN
SNPs/NNS
on/IN
OS/NN
or/CC
PFS/NN
were/VBD
presented/VBN
as/IN
HRs/NNS
and/CC
95/CD
%/NN
confidence/NN
intervals/NNS
(/(
CIs/NNS
)/)
./.
====================
The/DT
total/JJ
patient/NN
dataset/NN
was/VBD
used/VBN
for/IN
the/DT
analysis/NN
./.
====================
The/DT
same/JJ
analysis/NN
was/VBD
repeated/VBN
using/VBG
the/DT
diffuse/JJ
large/JJ
B-cell/NN
lymphoma/NN
(/(
DLBCL/NN
)/)
patients/NNS
treated/VBN
by/IN
R-CHOP/NN
./.
====================
All/DT
reported/VBN
p-values/NNS
are/VBP
two-sided/VBN
,/,
and/CC
statistical/JJ
analyses/NNS
were/VBD
performed/VBN
using/VBG
SAS/NN
version/NN
9.3/CD
(/(
SAS/NN
Institute/JJ
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NN
)/)
./.
====================
Clinical/JJ
characteristics/NNS
of/IN
NHL/NN
patients/NNS
and/CC
treatment/NN
outcomes/NNS
====================
The/DT
associations/NNS
between/IN
clinical/JJ
characteristics/NNS
and/CC
OS/NN
or/CC
PFS/NN
are/VBP
summarized/VBN
in/IN
Tables/NNS
1/CD
and/CC
2/CD
./.
====================
The/DT
most/JJS
common/JJ
histologic/JJ
type/NN
was/VBD
DLBCL/NN
(/(
n/NN
=/JJ
83/CD
)/)
;/:
others/NNS
included/VBD
T-cell/NN
lymphoma/NN
(/(
n/NN
=/JJ
18/CD
)/)
,/,
mantle/NN
cell/NN
lymphoma/NN
(/(
n/NN
=/JJ
6/CD
)/)
,/,
and/CC
others/NNS
(/(
n/NN
=/JJ
5/CD
)/)
./.
====================
Univariable/JJ
results/NNS
showed/VBD
age/NN
,/,
gender/RB
,/,
performance/RB
status/NN
,/,
extra-nodal/JJ
involvement/NN
,/,
and/CC
IPI/NN
as/IN
being/VBG
significantly/RB
associated/VBN
with/IN
OS/NN
and/CC
PFS/NN
in/IN
the/DT
total/JJ
patient/NN
dataset/NN
,/,
with/IN
p-values/NNS
less/RBR
than/IN
0.05/CD
./.
====================
Variables/NNS
that/DT
were/VBD
significant/JJ
in/IN
the/DT
univariable/JJ
results/NNS
were/VBD
used/VBN
in/IN
the/DT
multivariable/JJ
analysis/NN
./.
====================
Using/VBG
the/DT
backward/JJ
variable/JJ
selection/NN
method/NN
in/IN
the/DT
multivariable/JJ
model/NN
,/,
male/JJ
,/,
performance/RB
status/NN
2/CD
,/,
and/CC
extra-nodal/JJ
involvement/NN
were/VBD
highly/RB
associated/VBN
with/IN
a/DT
poor/JJ
prognosis/NN
for/IN
OS/NN
and/CC
PFS/NN
equally/RB
./.
====================
In/IN
addition/NN
,/,
age/NN
was/VBD
also/RB
significantly/RB
associated/VBN
with/IN
PFS/NN
./.
====================
A/DT
subgroup/NN
analysis/NN
using/VBG
DLBCL/NN
patients/NNS
treated/VBN
by/IN
R-CHOP/NN
showed/VBD
a/DT
similar/JJ
trend/NN
,/,
except/IN
for/IN
age/NN
and/CC
performance/NN
status/NN
,/,
as/IN
the/DT
multivariable/JJ
result/NN
for/IN
PFS/NN
./.
====================
IL10/NN
polymorphisms/NNS
and/CC
survival/NN
====================
Genotype/NN
frequencies/NNS
of/IN
four/CD
SNPs/NNS
in/IN
the/DT
IL10/NN
gene/NN
are/VBP
listed/VBN
in/IN
Tables/NNS
3/CD
and/CC
4/CD
./.
====================
The/DT
MAF/NN
of/IN
rs1800872/NN
was/VBD
the/DT
highest/JJS
among/IN
the/DT
four/CD
SNPs/NNS
./.
====================
Of/IN
the/DT
four/CD
polymorphisms/NNS
,/,
rs1800871/NN
and/CC
rs1800872/NN
of/IN
the/DT
IL10/NN
gene/NN
represented/VBN
a/DT
marginal/JJ
association/NN
with/IN
both/DT
OS/NNS
(/(
p/NN
=/JJ
0.094/CD
and/CC
p/NN
=/JJ
0.058/CD
)/)
and/CC
PFS/NN
(/(
p/NN
=/JJ
0.051/CD
and/CC
p/NN
=/JJ
0.077/CD
)/)
(/(
Tables/NNS
3/CD
and/CC
4/CD
)/)
in/IN
B-cell/NN
lymphoma/NN
patients/NNS
treated/VBN
by/IN
R-CHOP/NN
,/,
based/VBN
on/IN
additive/JJ
models/NNS
./.
====================
Using/VBG
an/DT
additive/JJ
model/NN
for/IN
the/DT
reference/NN
allele/NN
,/,
the/DT
HR/NN
for/IN
rs1800871/NN
was/VBD
0.64/CD
times/NNS
for/IN
OS/NN
(/(
95/CD
%/NN
CI/NN
,/,
0.38/CD
to/TO
1.08/CD
)/)
and/CC
0.60/CD
times/NNS
for/IN
PFS/NN
(/(
95/CD
%/NN
CI/NN
,/,
0.36/CD
to/TO
1.00/CD
)/)
as/IN
one/CD
minor/JJ
allele/NN
increases/VBZ
in/IN
B-cell/NN
lymphoma/NN
patients/NNS
treated/VBN
with/IN
an/DT
R-CHOP/NN
regimen/NNS
(/(
Tables/NNS
3/CD
and/CC
4/CD
)/)
./.
====================
This/DT
study/NN
showed/VBD
that/IN
rs1800871/NN
and/CC
rs1800872/NN
of/IN
IL10/NN
were/VBD
marginally/RB
associated/VBN
with/IN
the/DT
prognosis/NN
in/IN
NHL/NN
./.
====================
Especially/RB
among/IN
the/DT
subtypes/NNS
of/IN
NHL/NN
,/,
these/DT
two/CD
polymorphisms/NNS
had/VBD
a/DT
decreased/VBN
risk/NN
with/IN
the/DT
minor/JJ
allele/NN
for/IN
DLBCL/NN
./.
====================
It/PRP
suggests/VBZ
that/IN
IL10/NN
polymorphisms/NNS
might/MD
be/VB
prognostic/JJ
indicators/NNS
for/IN
such/JJ
patients/NNS
./.
====================
There/EX
have/VBP
been/VBN
many/JJ
reports/NNS
on/IN
the/DT
relationship/NN
between/IN
IL10/NN
gene/NN
polymorphisms/NNS
and/CC
the/DT
risk/NN
of/IN
lymphoma/NN
,/,
including/VBG
meta-analyses/NNS
./.
====================
These/DT
studies/NNS
reported/VBD
that/IN
IL10/NN
(/(
rs1800890/NN
,/,
rs1800896/NN
,/,
rs1800871/NN
,/,
and/CC
rs1800872/NN
)/)
polymorphisms/NNS
are/VBP
associated/VBN
with/IN
the/DT
risk/NN
of/IN
NHL/NN
./.
====================
These/DT
polymorphisms/NNS
had/VBD
a/DT
significantly/RB
increased/VBD
risk/NN
for/IN
DLBCL/NN
and/CC
follicular/JJ
lymphoma/NN
[/(
1112/CD
]/)
./.
====================
These/DT
results/NNS
showed/VBD
the/DT
opposite/JJ
effects/NNS
compared/VBN
with/IN
our/PRP$
study/NN
./.
====================
However/RB
,/,
all/DT
of/IN
the/DT
polymorphisms/NNS
were/VBD
not/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
NHL/NN
./.
====================
In/IN
another/DT
study/NN
,/,
the/DT
rs1800896/NN
reference/VBP
allele/NN
was/VBD
associated/VBN
with/IN
an/DT
increased/VBN
risk/NN
of/IN
NHL/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
rs1800871/NN
and/CC
rs1800872/NN
had/VBD
no/DT
association/NN
with/IN
the/DT
risk/NN
of/IN
NHL/NN
[/(
13/CD
]/)
./.
====================
For/IN
an/DT
association/NN
with/IN
clinical/JJ
outcomes/NNS
,/,
a/DT
previous/JJ
study/NN
reported/VBD
that/IN
IL10/NN
gene/NN
polymorphisms/NNS
influenced/VBN
OS/NN
in/IN
T-cell/NN
lymphoma/NN
NHL/NN
[/(
14/CD
]/)
./.
====================
In/IN
another/DT
study/NN
,/,
IL10/NN
genotypes/NNS
were/VBD
associated/VBN
with/IN
a/DT
lower/JJR
production/NN
of/IN
anti-inflammatory/JJ
Th2/NN
cytokines/NNS
as/IN
a/DT
factor/NN
influencing/VBG
an/DT
unfavorable/JJ
course/NN
of/IN
NHL/NN
[/(
15/CD
]/)
./.
====================
However/RB
,/,
the/DT
other/JJ
study/NN
showed/VBD
no/DT
difference/NN
of/IN
allele/NN
frequencies/NNS
between/IN
lymphoma/NN
patients/NNS
and/CC
healthy/JJ
controls/NNS
,/,
and/CC
moreover/RB
,/,
they/PRP
did/VBD
not/RB
show/VB
any/DT
association/NN
of/IN
OS/NN
or/CC
event-free/RB
survival/NN
with/IN
IL10/NN
genotypes/NNS
[/(
16/CD
]/)
./.
====================
Our/PRP$
study/NN
has/VBZ
several/JJ
limitations/NNS
./.
====================
Our/PRP$
study/NN
has/VBZ
a/DT
limited/JJ
number/NN
of/IN
patients/NNS
./.
====================
Furthermore/RB
,/,
these/DT
subtypes/NNS
,/,
such/JJ
as/IN
mantle/NN
cell/NN
lymphoma/NN
and/CC
T-cell/NN
lymphoma/NN
,/,
were/VBD
not/RB
common/JJ
,/,
and/CC
fewer/JJR
studies/NNS
reported/VBD
an/DT
association/NN
between/IN
IL10/NN
gene/NN
polymorphisms/NNS
and/CC
these/DT
subtypes/NNS
./.
====================
Therefore/RB
,/,
the/DT
sample/NN
size/NN
was/VBD
limited/VBN
,/,
and/CC
the/DT
statistical/JJ
power/JJR
may/MD
be/VB
insufficient/JJ
./.
====================
Although/IN
our/PRP$
study/NN
has/VBZ
a/DT
limited/JJ
number/NN
of/IN
patients/NNS
,/,
it/PRP
gave/VBD
us/PRP
implications/NNS
for/IN
the/DT
association/NN
of/IN
IL10/NN
genotypes/NNS
and/CC
the/DT
prognosis/NN
of/IN
B-cell/NN
lymphoma/NN
treated/VBN
by/IN
R-CHOP/NN
,/,
which/WDT
is/VBZ
a/DT
standard/JJ
therapy/NN
./.
====================
Thus/RB
,/,
we/PRP
need/VBD
to/TO
further/RBR
study/NN
this/DT
on/IN
a/DT
large/JJ
scale/JJ
to/TO
confirm/VB
these/DT
results/NNS
./.
====================
HRs/NNS
of/IN
clinical/JJ
characteristics/NNS
of/IN
patients/NNS
with/IN
non-Hodgkin/JJ
lymphoma/NN
for/IN
overall/JJ
survival/NN
and/CC
progression-free/JJ
survival/NN
(/(
n/NN
=/JJ
112/CD
)/)
====================
HRs/NNS
of/IN
clinical/JJ
characteristics/NNS
of/IN
patients/NNS
with/IN
B-cell/NN
lymphoma/NN
treated/VBN
by/IN
R-CHOP/NN
for/IN
overall/JJ
survival/NN
and/CC
progression-free/JJ
survival/NN
(/(
n/NN
=/JJ
90/CD
)/)
====================
HRs/NNS
of/IN
IL10/NN
genotypes/NNS
for/IN
overall/JJ
survival/NN
in/IN
patients/NNS
with/IN
non-Hodgkin/JJ
lymphoma/NN
====================
HRs/NNS
of/IN
IL10/NN
genotypes/NNS
for/IN
progression-free/JJ
survival/NN
in/IN
patients/NNS
with/IN
non-Hodgkin/JJ
lymphoma/NN
====================
